BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11156227)

  • 1. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level.
    Ando M; Minami H; Ando Y; Saka H; Sakai S; Yamamoto M; Sasaki Y; Shimokata K; Hasegawa Y
    Clin Cancer Res; 2000 Dec; 6(12):4733-8. PubMed ID: 11156227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
    Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
    Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula.
    Nagao S; Fujiwara K; Imafuku N; Kagawa R; Kozuka Y; Oda T; Maehata K; Ishikawa H; Koike H; Aotani E; Kohno I
    Gynecol Oncol; 2005 Nov; 99(2):327-33. PubMed ID: 16005943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies.
    de Lemos ML; Hsieh T; Hamata L; Levin A; Swenerton K; Djurdjev O; Vu T; Hu F; Conklin J; Malfair Taylor SC
    Gynecol Oncol; 2006 Dec; 103(3):1063-9. PubMed ID: 16875719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flat dosing of carboplatin is justified in adult patients with normal renal function.
    Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
    Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia.
    Herrington JD; Tran HT; Riggs MW
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):241-7. PubMed ID: 16133538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin.
    Holweger K; Lipp HP; Beijnen JH; Bokemeyer C; Hartmann JT
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):693-701. PubMed ID: 21136060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing.
    Ando Y; Minami H; Saka H; Ando M; Sakai S; Shimokata K
    Br J Cancer; 1997; 76(8):1067-71. PubMed ID: 9376268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer.
    Shimokata T; Ando Y; Yasuda Y; Hamada A; Kawada K; Saito H; Matsuo S; Kondo M; Imaizumi K; Hasegawa Y
    Cancer Sci; 2010 Dec; 101(12):2601-5. PubMed ID: 20860621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.
    Donahue A; McCune JS; Faucette S; Gillenwater HH; Kowalski RJ; Socinski MA; Lindley C
    Cancer Chemother Pharmacol; 2001 May; 47(5):373-9. PubMed ID: 11391850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
    Niioka T; Uno T; Yasui-Furukori N; Takahata T; Shimizu M; Sugawara K; Tateishi T
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):575-80. PubMed ID: 16912889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Differences between the glomerular filtration rate estimated by the MDRD equation and the measurement of creatinine and urea clearance in unselected patients with terminal renal insufficiency].
    Caravaca F; Arrobas M; Luna E; Naranjo M; Pizarro JL; Sánchez-Casado E
    Nefrologia; 2002; 22(5):432-7. PubMed ID: 12497744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of expected AUC of carboplatin (CBDCA) predicted by Chatelut's formula in comparison with Calvert's].
    Nakamura T; Onishi Y; Kono T; Maeda T; Wada T; Hatae M
    Gan To Kagaku Ryoho; 1997 Mar; 24(5):579-83. PubMed ID: 9087291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
    Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K; Gervais A; Aikin A; Egorin M; Balis FM
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
    Ekhart C; Rodenhuis S; Schellens JH; Beijnen JH; Huitema AD
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):115-22. PubMed ID: 18989671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.
    Schmitt A; Gladieff L; Lansiaux A; Bobin-Dubigeon C; Etienne-Grimaldi MC; Boisdron-Celle M; Serre-Debauvais F; Pinguet F; Floquet A; Billaud E; Le Guellec C; Penel N; Campone M; Largillier R; Capitain O; Fabbro M; Houede N; Medioni J; Bougnoux P; Lochon I; Chatelut E
    Clin Cancer Res; 2009 May; 15(10):3633-9. PubMed ID: 19401344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
    Huitema AD; Mathôt RA; Tibben MM; Schellens JH; Rodenhuis S; Beijnen JH
    Clin Pharmacol Ther; 2000 Jun; 67(6):621-30. PubMed ID: 10872644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose individualization can minimize nephrotoxicity due to carboplatin therapy in patients with ovarian cancer.
    Donadio C; Lucchesi A; Ardini M; Cosio S; Fanucchi A; Gadducci A
    Ther Drug Monit; 2009 Feb; 31(1):63-9. PubMed ID: 19077927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Usefulness of the formula for predicting creatinine clearance from serum cystatin C].
    Oyabu C; Hayashi N; Sugiyama D; Umezu M; Kinoshita S; Hayashi H; Kawano S; Kumagai S
    Rinsho Byori; 2008 Dec; 56(12):1093-9. PubMed ID: 19175073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.